A Randomized, Double-blind, Double-dummy, Parallel-group Study Comparing the Efficacy and Safety of Ofatumumab Versus Teriflunomide in Patients With Relapsing Multiple Sclerosis

Trial Profile

A Randomized, Double-blind, Double-dummy, Parallel-group Study Comparing the Efficacy and Safety of Ofatumumab Versus Teriflunomide in Patients With Relapsing Multiple Sclerosis

Recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs Ofatumumab (Primary) ; Teriflunomide
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms ASCLEPIOS I
  • Sponsors Novartis
  • Most Recent Events

    • 27 Jun 2017 Trial desing for two parallel adaptive design studies presented at the 3rd Congress of the European Academy of Neurology
    • 05 Jun 2017 Planned primary completion date changed from 1 Jul 2019 to 15 May 2019.
    • 28 Apr 2017 Trial design presented at the 69th Annual Meeting of the American Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top